• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

    Gabrielle Lakusta
    Jan. 26, 2018 09:26AM PST
    Biotech Investing

    Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten public offering of 4,255,000 shares of its common stock, which included the exercise in full of the option to purchase 555,000 additional shares, at a price of $14.00 per share. As quoted in the press release: …

    Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten public offering of 4,255,000 shares of its common stock, which included the exercise in full of the option to purchase 555,000 additional shares, at a price of $14.00 per share.
    As quoted in the press release:

    Stemline intends to use the net proceeds from this offering for (i) clinical, regulatory, manufacturing and, if and when approved, potential commercial activities of SL‑401; (ii) clinical development of SL‑801 and SL‑701; (iii) research and development activities; (iv) potential acquisitions and in-licensing; and (v) other general corporate purposes.

    Click here to read the full press release.

    clinical-stage biopharmaceutical companystemline therapeuticsnet proceedsunderwritten public offeringpublic offeringclinical-stage biopharmaceutical
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×